Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All casirivimab/imdevimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchCasirivimab/imdevimabCasirivimab/i.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization 85% Improvement Relative Risk Hospitalization/ER 92% Symp. case 33% primary Weeks with high viral load 40% Casirivimab/i..  O'Brien et al.  EARLY TREATMENT  DB RCT Is early treatment with casirivimab/imdevimab beneficial for COVID-19? Double-blind RCT 204 patients in multiple countries (Jul 2020 - Jan 2021) Fewer hosp./ER visits (p=0.029) and symptomatic cases (p=0.04) c19early.org O'Brien et al., JAMA, January 2022 Favors casirivimab/im.. Favors control

Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial

O'Brien et al., JAMA, doi:10.1001/jama.2021.24939768
Jan 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
17th treatment shown to reduce risk in March 2021
 
*, now known with p = 0.000018 from 28 studies, recognized in 42 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
RCT 204 asymptomatic COVID+ patients, 100 treated with subcutaneous casirivimab/imdevimab, showing lower development of symptoms, lower hospitalization, and faster viral clearance with treatment. Study conducted prior to widespread circulation of delta and omicron in the study locations.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for many omicron variants Haars, Liu, Pochtovyi, Sheward, Tatham, VanBlargan.
risk of hospitalization, 85.5% lower, RR 0.15, p = 0.25, treatment 0 of 100 (0.0%), control 3 of 104 (2.9%), NNT 35, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization/ER, 92.2% lower, RR 0.08, p = 0.03, treatment 0 of 100 (0.0%), control 6 of 104 (5.8%), NNT 17, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of symptomatic case, 33.0% lower, RR 0.67, p = 0.04, treatment 29 of 100 (29.0%), control 44 of 104 (42.3%), NNT 7.5, odds ratio converted to relative risk, day 14, primary outcome.
relative weeks with high viral load, 39.7% better, RR 0.60, p = 0.001, treatment 100, control 104.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
O'Brien et al., 14 Jan 2022, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 38 authors, study period 13 July, 2020 - 28 January, 2021.
This PaperCasirivimab/i..All
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection
Meagan P O’brien, MD Eduardo Forleo-Neto, PhD Neena Sarkar, MD Flonza Isa, PhD; Peijie Hou, PhD Kuo-Chen Chan, PhD Bret J Musser, MD Katharine J Bar, MD Ruanne V Barnabas, MD Dan H Barouch, PhD Myron S Cohen, MD Christopher B Hurt, MD Dale R Burwen, MD, MPH Mary A Marovich, MD Elizabeth R Brown, ScD Ingeborg Heirman, PhD; John D Davis, PhD; Kenneth C Turner, PhD; Divya Divya Ramesh, PhD Adnan Mahmood, MD Andrea T Hooper, PhD Jennifer D Hamilton, PhD Yunji Kim, PharmD Lisa A Purcell, PhD Alina Baum, PhD Christos A Kyratsous, PhD; James Krainson, MD Richard Perez-Perez, DO Rizwana Mohseni, MS Bari Kowal, A Thomas Dicioccio, MD, DrPH Gregory P Geba, PhD Neil Stahl, PhD Leah Lipsich, MD Ned Braunstein, MD Gary Herman, MD George D Yancopoulos, PhD; David M Weinreich, Neal Warshoff, Liudmila Moreiras, Dario Altamirano, Dickson Ellington, Faisal Faikih, William Smith, Richard Gibson, Katie Buckner, Robert Rosen, Amy Sapp, Anita Kohli, Vicki Mcintyre, Yessica Sachdeva, Amanda Mcfarland, Dina Gibson, Kenneth Kim, Jason Ahn, Lisa Neinchel, Nayna Paryani, Amber Mottola, Eva Day, Martha Navarro, Rafaelito Victoria, Xanthe Victoria, Rene Uong, Mindy Sampson, Christopher Polk, Michael Leonard, Lewis Mccurdy, Leigh A Medaris, Zainab Shahid, Lisa Davidson, Jawad Nazir, John Lee, Amy Elliott, Swami Sathyanaryan, Mansi Oberoi, Muhammad (danial) Siddiqui, Muhammad Arsad, Kara Bruning, Sybil Hosek, Temitope Oyedele, Vanessa Sarda, Monica Mercon, Kathryn Stephenson, Boris Juelg, Chen Sabrina Tan, Rebecca Zash, Ai-Ris Collier, Jessica Ansel, Kate Jaegle, Lilia Roque-Guerrero, Ana Gomez Ramirez, Javier Capote, Gisel Paz, Michael Paasche-Orlow, Julien Dedier, Sanjay Vadgama, Ramachandra Patak, Nicolas Chronos, Cary Hefty, Judith Borger, Ifeanyi Momodu, Lindsey Carswell, Benjamin King, Ryan Starr, Scott Syndergaard, Nancy Patel, Ravikumar Patel, Ryan Sattar, Jeffrey Unger, Sheila De Jesus-Maranan, Cecilia Casaclang, Michael Seep, Celeste Brown, Joshua Whatley, Dennis Levinson, Saad Alvi, Norman James, Azazuddin Ahmed, Robinson Koilpillai, Stephanie Cassady, Jennifer Cox, Eduardo Torres, Mark J Rosenthal, Michael Winnie, Jerry Plemons, Omesh Verma, Richard Leggett, Ramon Reyes, Keith Beck, Brian Poliquin, Murtaza Mussaji, Jignesh Shah, David Sutton, Edward Pereira, Rodel Gloria, Stacey Kelly, Amy Dennis-Saltz, Mae Sheikh-Ali, Elias Saikali, James Magee, Rebecca Goldfaden, Haresh Boghara, Sunny Patel, Bari Eichelbaum, Duane Anderson, Sean Su, Alexander Akhavan, Diana Kirby, Joy Venglik, Kenneth Mayer, Taimur Khan, Marcy Gelman, Faisal A Fakih, Faisal M Fakih, Daniel Layish, Fernando Alvarado, Jose Diaz, Augusto Focil, Griselda Rosas, Stevan Correa, Michael Bogseth, Bhaktasharan Patel, Gary Tarshis, Katrina Grablin, Paul Simonelli, Stanley Martin, Alvin Sharma, Anna Chen, Pragya Dhaubhadel, Shaeesta Khan, Sreelatha Naik, Sudheer Penupolu, Thulashie Sivarajah, Tae-Sung Kwon, Lakshmi Saladi, Farbod Raiszadeh, Sharon Mannheimer, Raji Ayinla, Khaing Myint, Akari Kyaw, Donna Dowie, Robin O'reilly, Hussein Assallum, Lovelyamma Varghese, Ellen Morrison, Julie Franks, Jun Avelino Loquere, Orlando Rosario, Andrea Low, Joan Villacrucis, Alan Skolnick, Harold Minkowitz, David Leiman, Todd Price, Anatoli Krasko, Idisoro Wiener, Larry Reed, Oscar Lin, PhD; Divya Mayur Ramesh, George Alangaden, Suraj Saggar, Thomas Birch, Benjamin De La Rosa, Karyna Neyra, Erina Kunwar, Jeffrey Kingsley, April Pixler, Veronica Mcbride, Judith Aberg, Michelle Cespedes, Alexandra Abrams-Downey, Erna Kojic, Luz Lugo, Sean Liu, Nadim Salomon, David Perlman, Deena Altman, Farah Rahman, Georgina Osorio, Joseph Mathew, Sanjana Koshy, Dana Mazo, Francesca Cossarini, Sondra Middleton, Alina Jen, Erika Maria Reategui Schwarz, Miguel Trevino, Benjamin Devries, Vidya Menon, Moiz Kasubhai, Usha Venugopal, Anjana Pillai, Franscene Oulds, Matthew Hong, Wayne Harper, Lynn Eckert, Douglas Wadeson, Lisa Cohen, Joel Chua, Shyam Kottilil, Jennifer Husson, John Baddley, R Gentry Wilkerson, Shivakumar Narayanan, Uzoamaka Eke, Myint Noe, Melanie Malave Sanchez, Arthur Kim, Greg Robbins, Mark Siedner
JAMA, doi:10.1001/jama.2021.24939
CoV-2 treatments may be used to prevent progression from asymptomatic infection to symptomatic disease and to reduce viral carriage. OBJECTIVE To evaluate the effect of combination subcutaneous casirivimab and imdevimab on progression from early asymptomatic SARS-CoV-2 infection to symptomatic COVID-19. DESIGN, SETTING, AND PARTICIPANTS Randomized, double-blind, placebo-controlled, phase 3 trial of close household contacts of a SARS-CoV-2-infected index case at 112 sites in the US, Romania, and Moldova enrolled July 13, 2020-January 28, 2021; follow-up ended March 11, 2021. Asymptomatic individuals (aged Ն12 years) were eligible if identified within 96 hours of index case positive test collection. Results from 314 individuals positive on SARS-CoV-2 reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) testing are reported. INTERVENTIONS Individuals were randomized 1:1 to receive 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each; n = 158), or placebo (n = 156). MAIN OUTCOMES AND MEASURES The primary end point was the proportion of seronegative participants who developed symptomatic COVID-19 during the 28-day efficacy assessment period. The key secondary efficacy end points were the number of weeks of symptomatic SARS-CoV-2 infection and the number of weeks of high viral load (>4 log 10 copies/mL). RESULTS Among 314 randomized participants (mean age, 41.0 years; 51.6% women), 310 (99.7%) completed the efficacy assessment period; 204 were asymptomatic and seronegative at baseline and included in the primary efficacy analysis. Subcutaneous casirivimab and imdevimab, 1200 mg, significantly prevented progression to symptomatic disease (29/100 [29.0%] vs 44/104 [42.3%] with placebo; odds ratio, 0.54 [95% CI, 0.30-0.97]; P = .04; absolute risk difference, −13.3% [95% CI, −26.3% to −0.3%]). Casirivimab and imdevimab reduced the number of symptomatic weeks per 1000 participants (895.7 weeks vs 1637.4 weeks with placebo; P = .03), an approximately 5.6-day reduction in symptom duration per symptomatic participant. Treatment with casirivimab and imdevimab also reduced the number of high viral load weeks per 1000 participants (489.8 weeks vs 811.9 weeks with placebo; P = .001). The proportion of participants receiving casirivimab and imdevimab who had 1 or more treatment-emergent adverse event was 33.5% vs 48.1% for placebo, including events related (25.8% vs 39.7%) or not related (11.0% vs 16.0%) to COVID-19. CONCLUSIONS AND RELEVANCE Among asymptomatic SARS-CoV-2 RT-qPCR-positive individuals living with an infected household contact, treatment with subcutaneous casirivimab and imdevimab antibody combination vs placebo significantly reduced the incidence of symptomatic COVID-19 over 28 days.
Conflict of Interest Disclosures: Drs O'Brien, Isa, Turner, Hamilton, and Herman are Regeneron employees/stockholders and have a patent pending, which has been licensed and is receiving royalties, with Regeneron. Drs Forleo-Neto, Sarkar, Hou, Chan, Musser, Davis, Ramesh, Mahmood, Kim, DiCioccio, Lipsich, Braunstein, and Weinreich Role of the Funder/Sponsor: Regeneron Pharmaceuticals Inc in collaboration with the CoVPN and the NIAID were involved in the design and conduct of the study. Regeneron and CoVPN were involved in the collection and management of data. Regeneron analyzed the data. Regeneron, the NIAID, and the CoVPN were involved in interpretation of the data; were responsible for preparation, review, and approval of the manuscript; and were involved in the decision to submit the manuscript for publication. Regeneron did not have the right to veto publication. The trial sites were funded by Regeneron or were part of the CoVPN, funded by the NIAID. Group Information: The members of the COVID-19 Phase 3 Prevention Trial Team are listed in Supplement 3. Disclaimer: The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Data Sharing Statement: See Supplement 4. Additional Contributions: We thank the study participants and their families; the investigational site members involved in this trial; the COVID-19 Phase 3 Prevention Trial Team; the members of the data and safety monitoring..
References
Baum, Ajithdoss, Copin, REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters, Science, doi:10.1126/science.abe2402
Baum, Fulton, Wloga, Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies, Science, doi:10.1126/science.abd0831
Boutron, Chaimani, Devane, Interventions for the prevention and treatment of COVID-19: a living mapping of research and living network meta-analysis, Cochrane Database Syst Rev, doi:10.1002/14651858.CD013769
Boyarsky, Werbel, Avery, Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients, JAMA, doi:10.1001/jama.2021.7489?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jama.2021.24939
Buitrago-Garcia, Egli-Gany, Counotte, Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis, PLoS Med, doi:10.1371/journal.pmed.1003346
Garcia-Beltran, Lam, Denis, Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity, Cell, doi:10.1016/j.cell.2021.03.013
Gisaid, hCov19 Variants
Hansen, Baum, Pascal, The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies, Science, doi:10.1016/j.cell.2021.06.002
Higdon, Wahl, Jones, A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease. medRxiv, doi:10.1101/2021.09.17.21263549
Isa, Hou, Chan, Musser, Bar et al., Statistical analysis: O
Kreuzberger, Hirsch, Chai, SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19, Cochrane Database Syst Rev, doi:10.1002/14651858.CD013825.pub2
Magesh, John, Li, Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic-review and meta-analysis, JAMA Netw Open, doi:10.1001/jamanetworkopen.2021.34147?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jama.2021.24939
O'brien, Forleo-Neto, Musser, Covid-19 Phase 3 Prevention Trial Team. Subcutaneous REGEN-COV antibody combination to prevent Covid-19, N Engl J Med, doi:10.1056/NEJMoa2109682
Portal-Celhay, Forleo-Neto, Eagan, Dose-ranging virology study of the combination COVID-19 antibodies casirivimab and imdevimab in the outpatient setting-poster 04769
Weinreich, Sivapalasingam, Norton, Trial Investigators. REGEN-COV antibody combination and outcomes in outpatients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2108163
Weinreich, Sivapalasingam, Norton, Trial Investigators. REGN-COV2, a neutralizing antibody cocktail
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit